Accès ouvert

Efficacy and Safety of Allogenic Canine Adipose Tissue-derived Mesenchymal Stem Cell Therapy for Insulin Dependent Diabetes Mellitus in Dogs: A pilot study

Article scientifique 2019 Anglais

Résumé

Abstract Background Since mesenchymal stem cells (MSCs) possess regenerative and immunomodulatory properties, and are capable of controlling the immune dysregulation that leads to β-cell destruction, stem cell transplantation could be used in the management of insulin-dependent diabetes mellitus (IDDM). In this pilot study, we assessed whether canine adipose tissue-derived MSC (cAT-MSC) therapy could be an option for treatment of canine diabetes mellitus. Results With the written informed consent of the owners, allogenic cAT-MSCs were infused intravenously in IDDM dogs. C-peptide was elevated by about 5–15% in 3 of 4 cases, and hyperlipidemia was resolved in 2 of 4 cases. Additionally, fructosamine and Hb/A1c levels were improved in 2 of 4 cases. Conclusions Considering that C-peptide secretion capacity and lipid metabolism are related to diabetic complications, these results suggest that cAT-MSC therapy in diabetic dogs might help to improve the insulin secretory capacity of dogs with IDDM and prevent diabetic complications.

Citer ce document

Rhew, S., Song, W., Li, Q., An, J., Chae, H., Jeung, S., Park, S., Lee, J., Cho, H., Sohn, S., Youn, H. (2019). Efficacy and Safety of Allogenic Canine Adipose Tissue-derived Mesenchymal Stem Cell Therapy for Insulin Dependent Diabetes Mellitus in Dogs: A pilot study. https://doi.org/10.21203/rs.2.12448/v1

Accès au document

Voir sur le dépôt source

Ce document est hébergé sur son dépôt institutionnel d'origine.

Auteur(s)

Sung-Yong Rhew Woo‐Jin Song Qiang Li Ju‐Hyun An Hyung‐Kyu Chae So-Young Jeung Seol-Gi Park Jeong-Ha Lee Hee-Seon Cho Sang-June Sohn Hwa‐Young Youn

Statistiques

Consultations : 1

Téléchargements : 0